XM does not provide services to residents of the United States of America.

Financial software maker Enfusion explores options including sale, sources say



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>EXCLUSIVE-Financial software maker Enfusion explores options including sale, sources say</title></head><body>

By Milana Vinn

NEW YORK, Sept 20 (Reuters) -Enfusion ENFN.N, a U.S. software provider for asset managers, is in talks with investment bankers to evaluate its options that could include a potential sale, according to people familiar with the matter.

The Chicago, Illinois-based company, which has a market value of $1.1 billion, decided to interview investment banks in recent weeks after receiving takeover interest from potential suitors including private equity firms, one of the sources said, requesting anonymity as the matter is confidential.

Enfusion has not launched a sale process yet and it is possible that the company opts to stay independent, the sources added.

Enfusion did not immediately respond to requests for comment.

This is not the first time Enfusion has held talks to explore a deal. Reuters reported last year that Enfusion fielded acquisition interest from several potential acquirers, including Francisco Partners, Vista Equity Partners and Irenic Capital Management.

Enfusion, whose customer base comprises mostly hedge funds, provides cloud-based portfolio management and risk systems to investment funds. The company has been attempting to win more business from larger funds and corporations with complex operations, as it has struggled to get a bigger share of revenues from existing customers.

Enfusion's shares, which have been trading in New York since their initial public offering in 2021 and have lost more than 50% of their value since then, are down about 12% so far this year, underperforming the S&P 500 Application Software index that has remained roughly flat, on concerns about its customers cutting spending.

The company reported year-on-year revenue growth of 16% to $49.5 million in its latest quarter, falling short of market expectations.

Investment firms FTV Management Company and ICONIQ Capital collectively own a roughly 50% stake in Enfusion.

Earlier this year, Spruce Point Management took a short position in Enfusion, as the investment firm did not believe the company was a high-quality software provider and said its revenue was at "high risk of misstatement."



Reporting by Milana Vinn in New York; Editing by Daniel Wallis

</body></html>

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.